Pulse Biosciences (NASDAQ:PLSE) Sees Large Volume Increase – What’s Next?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares saw unusually-strong trading volume on Thursday . 365,471 shares were traded during trading, an increase of 9% from the previous session’s volume of 334,136 shares.The stock last traded at $28.1040 and had previously closed at $28.11.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on PLSE shares. Canaccord Genuity Group began coverage on Pulse Biosciences in a research note on Thursday, June 4th. They issued a “buy” rating and a $32.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a report on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $30.67.

Pulse Biosciences Price Performance

The company has a market cap of $1.82 billion, a price-to-earnings ratio of -23.90 and a beta of 1.65. The business’s fifty day moving average price is $25.33 and its 200 day moving average price is $21.08.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.05. The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.25 million. As a group, equities research analysts anticipate that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Insider Activity

In other news, Director Robert W. Duggan purchased 660,233 shares of the stock in a transaction on Monday, May 11th. The stock was purchased at an average price of $19.69 per share, for a total transaction of $12,999,987.77. Following the acquisition, the director owned 48,211,433 shares in the company, valued at $949,283,115.77. This trade represents a 1.39% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Paul A. Laviolette purchased 15,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $19.69 per share, for a total transaction of $295,350.00. Following the transaction, the chief executive officer directly owned 15,000 shares in the company, valued at approximately $295,350. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 74.00% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Large investors have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its holdings in Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares during the period. Tower Research Capital LLC TRC grew its holdings in Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after acquiring an additional 2,156 shares during the period. Russell Investments Group Ltd. raised its position in shares of Pulse Biosciences by 44.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock worth $79,000 after acquiring an additional 1,372 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Pulse Biosciences in the 2nd quarter worth about $158,000. Finally, Brevan Howard Capital Management LP acquired a new position in shares of Pulse Biosciences in the 2nd quarter valued at about $215,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.